剂量翻三倍、月费仅涨50美元:诺和诺德(NVO.US)推高剂量Wegovy硬刚礼来(LLY.US)Zepbound

智通财经
Apr 07

智通财经APP获悉,诺和诺德(NVO.US)宣布,将面向自费患者,把新款高剂量减肥药Wegovy的价格定为每月399美元,这一定价低于其竞争对手礼来(LLY.US)旗下Zepbound多数规格的售价。

诺和诺德表示,高剂量版Wegovy将于本周二正式上市。该定价较礼来Zepbound前三档高剂量规格面向自费患者的售价,低出约40%。

这款更强效的药物是诺和诺德追赶礼来的重要战略一环。此前一项临床试验显示,Zepbound在减重效果上优于标准剂量的Wegovy。凭借更显著的减重效果,礼来该药物已成为美国最畅销的减肥注射剂。

诺和诺德寄希望于Wegovy新剂型实现业绩反弹。今年1月推出的口服版Wegovy,已创下迄今减肥药物史上最佳上市表现。上周,这家丹麦药企还推出订阅服务,患者若签订数月疗程,可享受更低的Wegovy月费。

这款名为Wegovy HD的新型注射剂,药物剂量达7.2毫克,是此前市售最高剂量的三倍,而月度自费价格仅高出50美元。自费患者可通过诺和诺德直营消费者平台NovoCare、常规药房渠道及指定远程医疗合作方购买。

诺和诺德发言人表示,根据合作的远程医疗机构不同,该新剂量产品将纳入部分订阅套餐,按标准订阅价提供。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10